Movement disorders in patients with schizophrenia and a history of substance abuse

Human Psychopharmacology

Volumn 28, Issue 2, 2013, Pages 192-197

  Hansen, Lars K ^a   Nausheen, Bina ^a,b   Hart, Deborah ^a   Kingdon, David ^a,b  

^a SOUTHERN HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

akathisia; alcohol; extrapyramidal side effects; movement disorder; schizophrenia; substance abuse

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ARTICLE; BARNES AKATHISIA SCALE; DISEASE ASSOCIATION; DISEASE DURATION; DRUG ABUSE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL PATIENT; PARKINSONISM; PRIORITY JOURNAL; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; TARDIVE DYSKINESIA;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 84875639408     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2305     Document Type: Article

References (21)

1. American Psychiatric Association. 1987. Diagnostic and Statistical Manual of Mental Disorders, (3th edn, rev.). Washington DC: American Psychiatric Association.
2. Bailey LG, Maxwell S, Brandabur MM,. 1997. Sustance abuse is a risk factor for tardive dyskinesia. Psychopharmacol Bull 33: 177-181.
3. Barnes TRE,. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
4. Berridge KC,. 2007. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology 191: 391-431.
5. Carey KB, Cocco KM, Simons JS,. 1996. Concurrent validity of clinicians' ratings of substance abuse among psychiatric outpatients. Psychiatr Serv 47: 842-847.
6. Cem Atbaşoglu E, Schultz SK, Andreasen NC,. 2001. The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia. Journal of Neuropsychiatry & Clinical Neuroscience 13: 336-341.
7. Duke PJ, Pantelis C, Barnes TR,. 1994. South Westminster schizophrenia survey: alcohol use and its relationship to symptoms, dyskinesia and illness onset. Br J Psychiatry 164: 630-6.
8. Grech A, Van Os J, Jones PB, et al,. 2005. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 20: 349-353.
9. Hansen L, Kingdon D,. 2006. Rating suicidality in schizophrenia: items on global scales (HoNOS and CPRS) correlate with a validated suicidality rating scale (InterSePT). Arch Suicide Res 10: 249-252.
10. Hansen LK, Jones RM, Kingdon D,. 2004. No association between akathisia or Parkinsonism and suicidality in treatment-resistant schizophrenia. J Psychopharmacol 18: 384-387.
11. Kane JM, Fleischhacker W, Hansen LK, et al,. 2009. Akathisia: an update focusing on second generation antipsychotics. J Clin Psychiatry 70: 627-643.
12. Koreki A, Tsunoda K, Suzuki T, et al,. 2011. Clinical and demographic characteristics associated with postural instability in patients with schizophrenia. J Clin Psychopharmacol 31: 16-21.
13. Krystal JH, D'Souza DC, Madonick S, et al,. 1999. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr Res 35: S35-S49.
14. Munetz M, Benjamin S,. 1988. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 39: 1172-1177.
15. Naber D, Lambert M,. 2009. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 23: 649-59.
16. Potvin S, Pampoulova A, Mancini-Marie A, et al,. 2006. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. Journal of Neurology & Neurosurgical Psychiatry 77: 796-798.
17. Schooler NR, Kane JM,. 1982. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39: 486-487.
18. Segarra R, Zabala A, Eguíluz JI, et al,. 2011. Cognitive performance and smoking in first-episode psychosis: the self-medication hypothesis. Eur Arch Psychiatry Clin Neurosci 261: 241-250.
19. Simpson GN, Angus JWS,. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 (suppl 44): 11-19.
20. Van Harten PN, van Trier JC, Horwitz EH, et al,. 1998. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry 59: 128-130.
21. Zhornitsky S, Stip E, Pampoulova T, et al,. 2010 Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Movement disorder 15;25(13): 2188-2194.